Page 16 - 《中国药科大学学报》2025年第5期
P. 16

学报
               548                 Journal of China Pharmaceutical University 2025, 56(5): 548 − 556


                        第二代蛋白精氨酸甲基转移酶                                 5 抑制剂的研究进展



                       胡浙棋 ,尹春香 ,毛慧欢,常艺清,朱启华,徐云根,龚国清 ,邹 毅                                           **
                               #
                                         #
                                                                                          *
                                                (中国药科大学药学院, 南京 211198)

               摘 要 蛋白精氨酸甲基转移酶             5(PRMT5)在多种癌症中高表达,近年来已成为癌症治疗的重要靶标。然而,第一代
               PRMT5 抑制剂缺乏选择性,导致显著的血液毒性,严重限制了其临床应用;第二代                        PRMT5 抑制剂通过特异性靶向甲硫腺苷
               磷酸化酶(MTAP)缺失的肿瘤细胞,而不影响正常细胞,从而显著提高了安全性和疗效。本文总结了                                 PRMT5 在  MTAP  缺
               失肿瘤细胞中的生物学机制,系统回顾了当前处于临床研究阶段的五款第二代                          PRMT5 抑制剂的研发历程、分子的结合模式
               以及最新的临床试验进展,旨在为该领域的进一步研究提供参考。
               关键词 蛋白精氨酸甲基转移酶           5;甲硫腺苷磷酸化酶;甲硫腺苷;合成致死
               中图分类号  R914       文献标志码 A             文章编号 1000−5048(2025)05−0548−09
                                                     doi:10.11665/j.issn.1000−5048.2025021201

                引用本文 胡浙棋,尹春香,毛慧欢,等. 第二代蛋白精氨酸甲基转移酶               5  抑制剂的研究进展    [J]. 中国药科大学学报,2025,56(5):548 −
                556.

                Cite  this  article  as:  HU  Zheqi,  YIN  Chunxiang,  MAO  Huihuan,  et  al.  Research  progress  on  second-generation  protein  arginine
                methyltransferase 5 inhibitors[J]. J China Pharm Univ, 2025, 56(5): 548 − 556.


               Research progress on second-generation protein arginine methyltransferase

               5 inhibitors
                                                                                                    *
                       #
                                      #
               HU Zheqi , YIN Chunxiang , MAO Huihuan, CHANG Yiqing, ZHU Qihua, XU Yungen, GONG Guoqing , ZOU Yi **
               School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China
               Abstract    Protein  arginine  methyltransferase  5  (PRMT5)  exhibits  elevated  expression  levels  in  a  variety  of
               cancers and has emerged as a critical target for cancer therapy in recent years. However, first-generation PRMT5
               inhibitors have exhibited inadequate selectivity, leading to significant hematological toxicity, thus limiting their
               clinical utility. The second-generation PRMT5 inhibitors have shown marked improvement in safety and efficacy
               by  selectively  targeting  MTAP-null  tumor  cells  without  impacting  normal  cells.  This  review  systematically
               summarizes the biological and functional roles of PRMT5 in MTAP-deficient tumor cells, and comprehensively
               analyzes the research and development process, molecular binding mechanisms, and the latest advancements in
               clinical trials of the five second-generation PRMT5 inhibitors currently under investigation, aiming to provide
               valuable insights for further in-depth studies in this field.
               Key words    protein  arginine  methyltransferase  5; methioadenosine  phosphorylase; methylthioadenosine;
                           synthetic lethal

               This study was supported by the National Innovation and Entrepreneurship Training Program for Undergraduate (202510316012Z)


               #
                HU Zheqi and YIN Chunxiang contributed equally to this work


                                              *
                    收稿日期 2025-02-12  通信作者     Tel:18021535796 E-mail:gonggq@hotmail.com
                                             **
                                                Tel:13260857396 E-mail:zouyi@cpu.edu.cn
                    基金项目    国家级大学生创新创业训练计划项目(202510316012Z)
                    胡浙棋和尹春香为共同第一作者
                    #
   11   12   13   14   15   16   17   18   19   20   21